We’re in the first week of the second Trump administration, and it’s becoming clearer how it might impact healthcare ...

Catalent to make Galapagos' CAR-T therapy, Kindeva gets $129M DuoDote contract, Solarbiotech/GPC Bio/Eleszto merge, Afrigen ...

Anthos Therapeutics' abelacimab shows lower bleeding risk vs Xarelto in atrial fibrillation trial, with 62% reduction in ...

FDA delays Stealth BioTherapeutics' elamipretide decision to April 29; Valneva's Ixchiq succeeds in child safety trial; TargetRx raises $50M; Ab&B Bio-Tech files for HKEX IPO ...

The FDA dodged claims from Vanda Pharmaceuticals that it allegedly violated the US Constitution by recommending the same drug ...

On the J&J's fourth-quarter earnings call, executives stood by Intra-Cellular’s projection that Caplyta could eclipse $5 ...

A little-known Chinese biotech startup has zipped ahead of US companies in one of the gene editing field’s most competitive ...

Samsung Biologics closed 2024 on several high notes, reaching its highest annual revenue to date — and just a week ago, ...

HHS Secretary nominee Robert F. Kennedy Jr. will divest his interests in several biopharma companies, including CRISPR ...

Not many biotechs survive beyond 25 years, let alone get multiple drugs approved and turn a profit. BioMarin Pharmaceutical has done all that, but finds itself navigating ...

AstraZeneca says it plans to participate in the next round of Medicare negotiations under the Inflation Reduction Act. But this time around, the company says it’s dealing with a whole different set of ...

Xilio's vilastobart plus Roche's Tecentriq shows partial responses in colorectal cancer trial, but company faces cash ...